A post-hoc analysis of a phase 3 trial demonstrated that adding 6 months of androgen deprivation therapy to salvage radiotherapy for recurrent prostate cancer following radical prostatectomy improves progression-free survival at 120 months.
Whole pelvis radiotherapy (WPRT) may improve treatment outcomes among patients with intermediate- or high-risk prostate cancer compared with prostate-only radiotherapy (PORT), a new study suggests. A team led by Peter J. Hoskin, MD, PhD, of Southampton General Hospital in Southampton, UK, compared the approaches in a prospective cohort study that included 812 men with intermediate-…
Among men with low-risk prostate cancer, the likelihood of biochemical failure is lower among patients who undergo low-dose-rate brachytherapy vs radical prostatectomy, data suggest.
In the TITAN trial, health-related quality of life did not worsen with the addition of apalutamide to ADT versus placebo for patients with metastatic castration-sensitive prostate cancer.
In mCRPC patients previously treated with docetaxel and either abiraterone or enzalutamide, third-line therapy with cabazitaxel offered longer imaging-based progression-free survival and overall survival compared with switching patients to the other antiandrogen, the CARD study found.
In a prospective cohort study of men who underwent radical treatment for prostate cancer, smoking duration of 10 or more years among ever-smokers was associated an increased risk of biochemical recurrence.
